GLP-1 medications, such as Wegovy and Zepbound, have become increasingly popular for weight management. While they are proven to be effective for weight loss and other conditions, the research is mixed on how these medications impact mental health and emotional well-being.
In this article, we’ll look at recent studies on how GLP-1s impact depression, anxiety, general mood, and other mental health indicators. We’ll also examine research on how these weight-loss medications affect eating disorder risk.
Quick Read
GLP-1 receptor agonists are medications that mimic a natural hormone released after eating, helping to regulate blood sugar and appetite. They can lead to significant weight loss—around 10 to 15 percent of body weight—which improves metabolic health and lowers blood pressure.
The FDA has approved these medications for teens aged 12 and older with obesity, offering a potential solution to adolescent obesity and its associated health risks. However, prescribing these medications requires careful consideration due to their impact on the developing brain and potential risks for eating disorders.
While GLP-1s are known to reduce bothersome “food noise” and reduce obsessive and intrusive thoughts about food by lowering food-related anxiety, they may also suppress appetite in ways that could exacerbate restrictive eating behaviors. Concerns about misuse among teens for cosmetic weight loss are growing, emphasizing the need for medical supervision.
How GLP-1 Weight Loss Medications Work
GLP-1 receptor agonists are medications that copy a natural hormone your gut releases after eating. These drugs work by activating certain receptors in the pancreas and brain to help regulate blood sugar and improve blood sugar control, including increasing insulin secretion after meals, supporting insulin secretion when glucose rises, and lowering blood sugar levels, while also slowing digestion and reducing appetite.
For many people, GLP-1s help them lose weight in a steady, lasting way. Many patients lose about 10 to 15 percent of body weight, a significant weight loss that can improve metabolic health and lower blood pressure.
Are GLP-1s Approved for Teen Use?
The FDA has approved semaglutide (the key ingredient in Wegovy) for teens 12 and older who are dealing with obesity, and liraglutide is approved for a similar age group. These medications can be a real breakthrough in addressing adolescent obesity, reducing risks for heart disease, diabetes, sleep problems, and even mental health challenges like depression and disordered eating.
But prescribing GLP-1s isn’t a straightforward decision. These drugs affect brain pathways that play a big role in mood, reward, and body image, which means understanding those connections is key.
How Do GLP-1 Medications Affect the Developing Brain?
It’s important to remember that the adolescent brain is still growing and changing, especially in the areas that control reward, decision-making, and dopamine regulation. These parts of the brain continue to develop well into a person’s mid-20s, which makes the effects of GLP-1 medications on teens and emerging adults more complex.
In adults, activating GLP-1 receptors in the brain’s reward system has been linked to reduced cravings—not just for food, but also for substances such as alcohol, opioids, and nicotine. This result has been a hopeful development in addiction treatment. But in teens, those same reward circuits are more sensitive and adaptable, so the effects of dampening dopamine-related signals can be less predictable.
Promising Benefits of GLP-1s on Brain Inflammation, Mood, and Self-Image
There is promising research showing that GLP-1s can reduce inflammation in the brain, which may help ease symptoms of depression and anxiety. Many patients, including teens, notice a calming of obsessive food-related thoughts. Reducing this “food noise” may support focus and emotional balance, making it one of the more notable mental health benefits of GLP-1s.
Can GLP-1s Make Eating Disorders Worse in Teens and Young Adults?
GLP-1 medications can be helpful for weight management, but they also come with potential risks—especially for teens and young adults who have or are vulnerable to eating disorders. Understanding these risks can help parents and caregivers watch for warning signs and support their loved ones safely.
“As the research around GLP-1 medications continues to evolve, we welcome the growing intersection of medical and behavioral health research. The more we understand about how these medications affect young people physically and psychologically, the better equipped we are to provide thoughtful, integrated care.”
Elizabeth McCarron MSS, LCSW
Regional Director of Outpatient Services, Centers for Families
How GLP-1s Affect Binge Eating
Some research shows that GLP-1 medications may reduce binge eating by lowering appetite and cravings. However, the response varies from person to person, and these medications are not approved for treating eating disorders. Moreover, they don’t address the underlying emotional or psychological causes of binge eating. Professional therapy and support remain essential parts of treatment.
Risks for Anorexia and Restrictive Eating
GLP-1 medications work by suppressing appetite, which can be risky for teens who have or are at risk for anorexia or other restrictive eating disorders. Because these drugs reduce hunger signals, they might unintentionally encourage extreme calorie restriction or make it feel “medically okay” to eat very little.
Rapid weight loss caused by GLP-1s can also make body image concerns worse, especially if a teen’s mind hasn’t caught up with the physical changes. This disconnect can increase anxiety and obsessive thoughts about food and weight, potentially triggering or worsening anorexia.
Elizabeth McCarron MSS, LCSW, Regional Director of Outpatient Services for Newport’s Center for Families division, says that when treating teens who are using GLP-1s and also present with eating disorders, close communication and collaboration between medical and psychiatric providers is essential.
“Our responsibility is to work together to understand the whole young person—their medical needs, mental health, and of course their relationship with food and body,” she said. “As the research around GLP-1 medications continues to evolve, we welcome the growing intersection of medical and behavioral health research. The more we understand about how these medications affect young people physically and psychologically, the better equipped we are to provide thoughtful, integrated care.”
Misuse and Off-Label Use Concerns
There’s growing concern about teens and young adults using GLP-1 medications without medical supervision, often to lose weight quickly or for cosmetic reasons. This off-label or non-prescribed use can be dangerous, especially without proper mental health monitoring.
Using these medications without guidance can increase the risk of developing or worsening eating disorders, as well as cause other physical and psychological side effects. It’s crucial that GLP-1 medications are prescribed and monitored by healthcare professionals who understand the unique needs of teens and young adults.
Mental Health Symptoms to Watch for After Starting GLP-1 Medication
The first few weeks and months after starting a GLP-1 medication are the most critical, as this is when psychological side effects are most likely to appear. Here are some key signs to watch for:
| Symptom Category | Specific Signs | What to Do |
| Mood | Increased irritability, persistent sadness, emotional numbness, anxiety | Monitor closely; seek mental health support if symptoms persist beyond first weeks |
| Sleep | Difficulty falling asleep, waking early, sleeping too much (hypersomnia) | Track sleep patterns; consult healthcare provider if disrupted sleep continues |
| Eating Behavior | Obsessive calorie counting, refusal of previously enjoyed foods, meal anxiety | Encourage open dialogue; seek evaluation for disordered eating if behaviors escalate |
| Body Image | Negative self-talk, linking self-worth to weight, expressing disgust/shame | Promote positive body image; consider therapy if distress interferes with daily life |
| Social Behavior | Withdrawal from friends, family, and activities | Encourage social engagement; seek professional help if isolation deepens |
Mental Health and GLP-1s: Research and Considerations
Here are some of the key areas in which research is being conducted on how GLP-1 medications like Wegovy and Ozempic impact mental health.
GLP-1s and Suicidal Thoughts
The Food and Drug Administration carefully reviews reports of suicidal ideation linked to GLP-1 medications. Some research suggests these drugs might reduce suicidal ideation in certain groups. But another study found that GLP-1 medications are associated with a higher risk of self-harm and suicidal thoughts.
If a teen or young adult ever talks about self-harm or suicide, don’t wait. Seek professional help immediately.
The Impact of GLP-1s on Pre-Existing Anxiety or Depression
Teens and young adults with pre-existing anxiety or depression are not automatically excluded from GLP-1 therapy, but their mental health history should be a central variable in the prescribing decision. The anti-inflammatory and reward-pathway effects of GLP-1 agonists mean that, for some young people, these medications may actually reduce depressive symptoms over time.
How Psychiatric Medications Interact with GLP-1s
For young people taking certain psychiatric medications, including SSRIs, SNRIs, or atypical antipsychotics for anxiety or depression, GLP-1s may slow down the absorption of these medications. This is called a pharmacokinetic interaction and requires monitoring and, in some cases, dosage adjustment.
The Psychological Impact of Rapid Weight Loss
When a young person’s body changes quickly through rapid weight loss, their mind often needs more time to catch up. Body image—the way someone sees themself and feels about their physical appearance—doesn’t update instantly when a person experiences physical changes. This disconnect can lead to:
- Increased anxiety
- Obsessive monitoring of food and weight
- A deeper preoccupation with eating
LGBTQ+ Youth, GLP-1s, and Body Image
LGBTQ+ youth face higher risks for eating disorders even before starting a weight-loss medication. The added stress of living in a world that often marginalizes their identity (known as minority stress) can increase body dissatisfaction and disordered eating behaviors.
For LGBTQ+ teens considering GLP-1 treatment, it’s especially important to ask providers about eating disorder screening before and during therapy. This is a crucial part of affirming, comprehensive care.
When to Seek Professional Help
Getting help early can make a big difference in outcomes, especially when mental health challenges arise during GLP-1 treatment. You don’t have to wait for a crisis before reaching out to a mental health professional.
If you or your loved one is experiencing signs of severe anxiety, disordered eating, or depression; withdrawing from social activities; or expressing suicidal thoughts, it’s important to seek help.
Mental Health and Eating Disorder Treatment at Newport Healthcare
Our programs combine expertise in eating disorders, mood disorders, and co-occurring conditions to provide comprehensive, individualized care. We offer specialized eating disorder treatment teens ages 12–18 and young adults ages 18–35 who are struggling with primary mental health and secondary eating disorders. Treatment at these specialized sites include:
- Dietary screenings, ongoing check-ins, and dietary groups with board-registered dietitians
- Body image groups and eating disorder–specific homework, using Cognitive Behavioral Therapy and Dialectical Behavioral Therapy skills
- Dietary plans and relapse prevention plans to take home, so clients can maintain and build on progress made in treatment
Contact Newport Healthcare today to learn more about our teen treatment at Newport Academy or our young adult treatment program at Newport Institute. Our compassionate team is here to listen, guide, and connect your family with the right resources.
